Furthermore, some ALK positive lung cancer patients do not exhibit significant tumor shrinkage with ALK-inhibitor treatment, suggesting refractory residual disease may result from compensatory signaling pathways [11, 35]. The gene discussed is ALK; the disease is neoplasm.